key: cord-0977849-rcnokzhr
authors: Mahdian, Soodeh; Zarrabi, Mahboobeh; Panahi, Yunes; Dabbagh, Somayyeh
title: Repurposing FDA-approved drugs to fight COVID-19 using in silico methods: Targeting SARS-CoV-2 RdRp enzyme and host cell receptors (ACE2, CD147) through virtual screening and molecular dynamic simulations
date: 2021-02-25
journal: Inform Med Unlocked
DOI: 10.1016/j.imu.2021.100541
sha: 1aa979b26ffd527490a3b90a34c1c35ad686b1a4
doc_id: 977849
cord_uid: rcnokzhr

BACKGROUND: Different approaches have been proved effective for combating the COVID-19 pandemic. Accordingly, in silico drug repurposing strategy, has been highly regarded as an accurate computational tool to achieve fast and reliable results. Considering SARS-CoV-2's structural proteins and their interaction the host's cell-specific receptors, this study investigated a drug repurposing strategy aiming to screen compatible inhibitors of FDA-approved drugs against viral entry receptors (ACE2 and CD147) and integral enzyme of the viral polymerase (RdRp). METHODS: The study screened the FDA-approved drugs against ACE2, CD147, and RDRP by virtual screening and molecular dynamics (MD) simulation. RESULTS: The results of this study indicated that five drugs with ACE2, four drugs with RDRP , and seven drugs with CD147 achieved the most favorable free binding energy (ΔG < -10). This study selected these drugs for MD simulation investigation whose results demonstrated that ledipasvir with ACE2, estradiol benzoate with CD147, and vancomycin with RDRP represented the most favorable ΔG. Also, paritaprevir and vancomycin have good binding energy with both targets (ACE2 and RdRp). CONCLUSIONS: Ledipasvir, estradiol benzoate, and vancomycin and paritaprevir are potentially suitable candidates for further investigation as possible treatments of COVID-19 and novel drug development.

removed during the process included compounds containing rare atoms and organometallic compounds. Eventually, 2471 compounds were selected.

The study used the Pyrx tool for virtual screening (27, 28) . The unit-docking cell was defined with Pockdrug server (29) and Uniprot databases. Input pdbqt files for Autodock Vina and minimization steps were generated by the Pyrx tool. Finally, to screen libraries of compounds against targets, the study implemented AutoDock Vina for drug discovery. Docking was done using a 92 A˚ × 84 A˚ × 98 A˚ binding site grid box for ACE2, a 120 A˚ × 110 A˚ × 117 A˚ binding site grid box for CD147 and a 140 A˚ × 122 A˚ × 111 A˚ binding site grid box for RdRp.

A total of the top eight poses were retained from the docking run. The interaction established in two dimensions was illustrated in Biovia Discovery Studio, and for 3D visualization of drug/target complexes, Molegro Virtual Docker was used (30).

The results of virtual screening indicated that five drugs with ACE2, four drugs with RdRp, and seven drugs with CD147 achieved the most favorable free binding energy (ΔG < -10 kcal/mol).

For further evaluations, these drugs were chosen for MD simulation to calculate the number of H-bonds and free energy of interaction. MD simulations were directed using the GROMACS 5.1.4 package (31) . The GROMOS 54a7 force field was utilized for the complexes (32) .The study used the ATB server for the preparation of the coordinates and topology of ligands. The study applied appropriate amounts of chloride ions and sodium to all simulation boxes to neutralize the system. Periodic Boundary Condition (PBC) was applied along every simulation box axis, and the SP3 water model was also utilized for system solvation (33) in each simulation system. The LINCS algorithms constrained all covalent bonds. MD simulations were done through a short-range electrostatic interaction as well as a 1.2 nm distance cutoff for the van der Waals interaction. The Particle Mesh Ewald (PME) algorithm calculated the long-range electrostatic interaction. The steepest descent algorithm fulfilled the energy minimization of all systems, and then the NVT ensemble for 500 ps equilibrated all the systems. Then, the NPT ensemble progressively directed the equilibration of each system and the Nose-Hoover algorithm temperature (34, 35) was preserved at a temperature of 310 K. During the NPT equilibration, the J o u r n a l P r e -p r o o f Parrinello-Rahman barostat (36) maintained the pressures at 1 bar. The MD simulation was completed for the complexes in 100 ns.

The nonpolar and polar interactions between CD147, ACE2, and RdRp with drugs are explainable by binding free-energy calculation. By exercising the MM-PBSA method, the binding free-energy was calculated using the g_mmpbsa tool (37) . The total amount of binding free-energy (∆G) is realized by adding up the nonpolar interaction free-energy (∆G ) and

the polar interaction free-energy (∆G ) that can be explained as follows:

Where ∆ , ∆ , ∆ , ∆ are respectively the electrostatic energy, polar solvation energy, van der Waals energy, nonpolar solvation energy.

This study applied virtual screening FDA-approved drugs against RdRp, ACE2, and CD147.

According to the results, five drugs with ACE2 , four drugs with RdRp , and seven drugs with CD147 achieved the most favorable free binding energy (Docking score < −10 kcal/mol) ( Table   1 ). The hydrogen bonding of docked molecules was calculated using Molegro Virtual Docker and Biovia Discovery Studio v.4.5. 2D (Supplementary data).

MD simulation for all complexes of the ACE2, RDRP, and CD147 with the top-selected drugs is performed for 100 ns. RMSD of alpha carbon atoms, RMSF of all amino acid residues, the number of hydrogen bonds, and free energy of interaction for the drug/protein complexes are investigated. 

This study assessed the potential of FDA-approved small molecules to disrupt the interaction of virus-host cell components and interfere with the viral proliferation mechanism using drug repurposing approaches. The SARS-CoV-2 ACE2 receptor is integral in cardiovascular and renal diseases, diabetes, and lung injury (38) . Furthermore, the observations indicated that the expression of ACE2 correlated with the infection severity in vitro, (15) which makes it a suitable candidate for pharmaceutical studies. Accordingly, many cases have been reported in which the administration of soluble ACE2 is observed as a competitive method for inhibiting virus binding to the host cell (39) . MD simulation results indicated that Ledipasvir with ACE2 had the most favorable ΔG (Table 2) . Also, the results of molecular docking in a relevant study showed that Ledipasvir could interfere with the binding of S protein to ACE2 (40) .The stable binding energy during 100 ns MD simulations (-399.338Kcal/mol), together with RMSD and RMSF, confirm J o u r n a l P r e -p r o o f Ledipasvir inhibitory effects. Additionally, paritaprevir has good binding energy with both ACE 2 and RdRp targets. In this study, paritaprevir-ACE2 in 0 to 100 ns, Asp 206, have a key part in the hydrogen interactions during MD simulation (Table 1) . Based on structural data, Asp 206 is located in the interaction surface with SARS-CoV-2 spike proteins (40) . Also, the complexes of ACE2 are stabilized by H-bonded interactions offered by residues that some of which are in the binding site (41) . The recent studies aiming at screening the FDA against SARS-CoV-2 proteins indicated that ledipasvir, paritaprevir, and simeprevir are promising medication candidates for COVID-19 treatment (42 ,43) . The clinical trials to evaluate the efficacy of ledipasvir in the treatment of COVID-19 are underway (44, 45) . Ledipasvir and paritaprevir are direct-acting antiviral (DAA) medications used as part of combination therapy to treat chronic Hepatitis C, which is an infectious liver disease due to HCV infection. The RdRp enzyme is involved in viral genome replication and transcription of structural and peripheral small guided mRNAs (sgmRNAs) (46) . Therefore, it has been considered a primary target for many antiviral drugs, such as Remdesivir (5). RdRp has conserved structural motifs like other polymerases, such as thumb (residues 816-932), palm (residues 860-815), and finger (residues 366-581) (47) .Vancomycin has the highest hydrogen bond with ACE2 and RdRp (Fig. 4) . Also, MD simulation results indicated that vancomycin with RdRp had the most favorable ΔG (Table 4 ). In commonly treated with an antibiotic known as vancomycin. However, it has a narrow treatment window and some patients react differently to the drug leading to sub-optimal vancomycin concentrations in patients (48) .As you can see in Tables 2 and 4 , sirolimus and dactinomycin also have suitable binding energy with ACE2 and RdRp. A recent study used a network-based drug repurposing sirolimus plus dactinomycin as treatment candidates for COVID-19 (49) .

Nowadays, CD147 is regarded as an integral target in treating inflammatory diseases (50) . In (Table 3) . A relevant study demonstrated that a combination of irinotecan (topoisomerase I inhibitor) and etoposide (a topoisomerase II inhibitor) can potentially inhibit cytokine storms in COVID-19 (55) . A type of clinical study using a drug repositioning strategy indicated the inhibitory effects of olaparib and mefuparib, as two PARP1 inhibitors, on COVID-19 (56). Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6), that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity.

The inhibition of CD147 and ACE2, as two main receptors of SARS-CoV-2, can prevent the entering of the virus into the host cells. Besides, the inhibition of RdRp, as the main enzyme for viral replication, is effective in fighting the COVID-19. Accordingly, this study aimed to use drug repurposing by virtual screening to identify inhibitors for CD147, ACE2, and RdRp. The J o u r n a l P r e -p r o o f results of this study showed that five drugs with ACE2, four drugs with RdRp, and seven drugs with CD147 achieved the most favorable free binding energy (Docking score < -10). These drugs were selected for MD simulation studies, the results of which indicated that ledipasvir with ACE2, estradiol benzoate with CD147, and vancomycin with RdRp had the most favorable ΔG.

Drugs that can inhibit major virus receptors (ACE2 and CD147) were found to be effective in the early stages of viral infection, and inhibition of RdRp can also prevent disease progression. It was also shown for the first time in this study that, paritaprevir and vancomycin have good binding energy with both targets (ACE2 and RdRp). These drugs can be suitable candidates for further investigation as possible treatments of COVID-19 infection.

The authors corroborate that this study has no conflict of interest.

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. J o u r n a l P r e -p r o o f 

A deterministic linear infection model to inform Risk-Cost-Benefit Analysis of activities during the SARS-CoV-2 pandemic

Genomic Characterisation and Epidemiology of 2019 Novel Coronavirus: Implications for Virus Origins and Receptor Binding

Observational study of hydroxychloroquine in hospitalized patients with Covid-19

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites

Rationale for considering oral Idasanutlin as a therapeutic option for COVID-19 patients

Experimental treatment with favipiravir for COVID-19: an open-label control study

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

Aftab Ahmad, and Nayla Munawar. Analysis of SARS-CoV-2 RNA-Dependent

RNA Polymerase as a Potential Therapeutic Drug Target Using a Computational Approach

Structure of the SARS-CoV Nsp12 Polymerase Bound to Nsp7 and Nsp8 Co-Factors

The Proximal Origin of SARS-CoV-2

Structural Basis for the Recognition of SARS-CoV-2 by Full-Length Human ACE2

Cryo-EM Structure of the 2019-NCoV Spike in the Prefusion Conformation

High Expression of ACE2 on Keratinocytes Reveals Skin as a Potential Target for SARS-CoV-2

NCoV (or SARS-CoV-2) Infection

Comparative Genetic Analysis of the Novel Coronavirus (2019-NCoV/SARS-CoV-2) Receptor ACE2 in Different Populations

DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications?

COVID-19 mediated by basigin can affect male and female fertility

Basigin (CD147), a Multifunctional Transmembrane Glycoprotein with Various Binding Partners

CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement

Basigin is a Receptor Essential for Erythrocyte Invasion by Plasmodium Falciparum

Influenza A Virus Infection Dysregulates the Expression of MicroRNA-22 and Its Targets; CD147 and HDAC4, in Epithelium of Asthmatics

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Crystal structure of HAb18G/CD147: implications for immunoglobulin superfamily homophilic adhesion

3Drefine: an interactive web server for efficient protein structure refinement

DrugBank 5.0: a major update to the DrugBank database for

Small-molecule library screening by docking with

Chemical Biology

AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading

PockDrug-Server: a new web server for predicting pocket druggability on holo and apo proteins

Molegro virtual docker for docking

Gromacs: A Message-Passing Parallel Molecular Dynamics Implementation

Optimization of the Additive Charmm All-Atom Protein Force Field Targeting Improved Sampling of the Backbone Φ, Ψ and Side-Chain Χ (1) and Χ (2) Dihedral Angles

A Parallel Linear Constraint Solver for Molecular Simulation

Canonical Dynamics: Equilibrium Phase-Space Distributions

Unified Formulation of the Constant Temperature Molecular Dynamics Methods

Polymorphic Transitions in Single Crystals: A New Molecular Dynamics Method

A. g_mmpbsa A GROMACS tool for high-throughput MM-PBSA calculations

Computational drug repurposing strategy predicted peptide-based drugs that can potentially inhibit the interaction of SARS-CoV-2 with its target (humanACE2)

The dual impact of ACE2 in COVID-19 and ironical actions in geriatrics and pediatrics with possible therapeutic solutions

Combined use of amentoflavone and ledipasvir could interfere with binding of spike glycoprotein of SARS-CoV-2 to ACE2: the results of molecular docking study

Investigation into SARS-CoV-2 resistance of compounds in garlic essential oil

Comparative docking of SARS-CoV-2 receptors antagonists from repurposing drugs

Drug repurposing of approved drugs Elbasvir, Ledipasvir, Paritaprevir, Velpatasvir, Antrafenine and Ergotamine for combating COVID19

Efficacy and safety of sofosbuvir/ledipasvir in treatment of patients with COVID-19; A randomized clinical trial

Experimental Pharmacotherapy for COVID-19: The Latest Advances

Continuous and discontinuous RNA synthesis in coronaviruses. Annual review of virology

Structure of the RNAdependent RNA polymerase from COVID-19 virus

Pharmacokinetics and Pharmacodynamics of Vancomycin in Severe COVID-19 Patients: a Preliminary Study in a Chinese Tertiary Hospital

Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell discovery

CD147: A Novel Modulator of Inflammatory and Immune Disorders

A novel small-molecule compound targeting CD147 inhibits the motility and invasion of hepatocellular carcinoma cells

Sex Hormones and Novel Corona Virus Infectious Disease (COVID-19)

Estradiol, progesterone, immunomodulation, and COVID-19 outcomes

Prevention and therapy of COVID-19 via exogenous estrogen treatment for both male and female patients

The AI-Discovered Etiology of COVID-19 and Rationale of the Irinotecan+